Drugs / Recombinant Human Interferon α2b
Recombinant Human Interferon α2b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05806918 | Apr → Jul 2023 | herpes zoster | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03266601 | Jun 2016 → Nov 2018 | herpangina | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT06827249 Comparator | Mar 2025 → Jun 2026 overdue | respiratory syncytial virus bronchiolitis | Children's Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT04273763 Background | Feb → May 2020 | COVID-19 | Second Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2006-10-18 | Lee's Pharmaceutical Limited | Regulatory New Indication Approved for Cervicitis for Yallaferon leespharm.com ↗
Yallaferon® ("Recombinant Human Interferon α-2b gel") has been approved for an additional indication for use in the treatment of cervicitis by the SFDA of China. |
| 2005-09-07 | Lee's Pharmaceutical Limited | Regulatory New Indication Approved for Yallaferon® leespharm.com ↗
Yallaferon® (Recombinant Human Interferon α-2b gel) has been approved for an additional indication for use in the treatment of herpes zoster by the SFDA of China. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2006-10-18 | Lee's Pharmaceutical Limited | New Indication Approved for Cervicitis for Yallaferon leespharm.com ↗ |
| 2005-09-07 | Lee's Pharmaceutical Limited | New Indication Approved for Yallaferon® leespharm.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human interferon α2b | “compared to recombinant human interferon α2b in the treatment of pediatric respiratory syncytial virus bronchiolitis.” NCT06827249 ↗ |
| Known as | Jeferon | “Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and...” NCT03266601 ↗ |
| Known as | Recombinant Human Interferon alpha 2b | “Recombinant Human Interferon alpha 2b, at a dose of 100,000 IU/kg” NCT06827249 ↗ |
| Known as | ZK-A03 | “The goal of this clinical trail is to demonstrate the non-inferiority of recombinant human interferon α-2b gel (ZK-A03) after changing the manufacturer of the active ingredient...” NCT05806918 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human interferon α-2b spray” NCT03266601 ↗ |
| Route | Other | “Recombinant human interferon α-2b spray” NCT03266601 ↗ |